Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments

Sander M Bison, Mark W Konijnenberg, Marleen Melis, Stefan E Pool, Monique R Bernsen, Jaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong, Sander M Bison, Mark W Konijnenberg, Marleen Melis, Stefan E Pool, Monique R Bernsen, Jaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong

Abstract

Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs abundantly express somatostatin receptors. Consequently, following administration of somatostatin (SST) analogs labeled with γ-emitting radionuclides, these tumors can be imaged for diagnosis, staging or follow-up purposes. Furthermore, when β-emitting radionuclides are used, radiolabeled peptides (radiopeptides) can also be used for the treatment for NET patients. Even though excellent results have been achieved with PRRT, complete responses are still rare, which means that there is room for improvement. In this review, we highlight some of the directions currently under investigation in pilot clinical studies or in preclinical development to achieve this goal. Although randomized clinical trials are still lacking, early studies have shown that tumor response might be improved by application of other radionuclides, such as α-emitters or radionuclide combinations, or by adjustment of radiopeptide administration routes. Individualized dosimetry and better insight into tumor and normal organ radiation doses may allow adjustment of the amount of administered activity per cycle or the number of treatment cycles, resulting in more personalized treatment schedules. Other options include the application of novel (radiolabeled) SST analogs with improved tumor uptake and radionuclide retention time, or a combination of PRRT with other systemic therapies, such as chemotherapy or treatment with radio sensitizers. Though promising directions appear to bring improvements of PRRT within reach, additional research (including randomized clinical trials) is needed to achieve such improvements.

Keywords: Dosimetry; Neuroendocrine tumor; Peptide receptor radionuclide therapy; Somatostatin analogs.

Figures

Fig. 1
Fig. 1
Decay of 225Ac; four consecutive α-particle-emitting daughters are formed during decay (color figure online)
Fig. 2
Fig. 2
Planar posterior image of the liver 24 h after i.v. and 24 h after i.a. administration of 111In-octreotide. LK left kidney, RK right kidney, S spleen, L liver, LM three liver metastases visible after i.a. injection. After i.a. administration, there was increased tumor uptake of 111In-octreotide

References

    1. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92(8):2204–2210. doi: 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>;2-R.
    1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. doi: 10.1002/cncr.11105.
    1. Yao JC, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi: 10.1200/JCO.2007.15.4377.
    1. Modlin IM, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4(5):526–547. doi: 10.1016/j.cgh.2005.12.008.
    1. Kwekkeboom DJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40(2):78–88. doi: 10.1053/j.semnuclmed.2009.10.004.
    1. Bodei L, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–2135. doi: 10.1007/s00259-011-1902-1.
    1. van Essen M, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34(8):1219–1227. doi: 10.1007/s00259-006-0355-4.
    1. Waldherr C, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12(7):941–945. doi: 10.1023/A:1011160913619.
    1. Taniyama Y, et al. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52(5):605–611. doi: 10.1507/endocrj.52.605.
    1. Reubi JC, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969–5977.
    1. Reubi JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836–846. doi: 10.1007/s002590100541.
    1. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198. doi: 10.1006/frne.1999.0183.
    1. Krenning EP, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–731. doi: 10.1007/BF00181765.
    1. Kwekkeboom DJ, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In -DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–1325. doi: 10.1007/s002590100574.
    1. Rosenberg JM. Octreotide: a synthetic analog of somatostatin. Drug Intell Clin Pharm. 1988;22(10):748–754.
    1. Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663. doi: 10.1200/JCO.2009.22.8510.
    1. Ambrosini V, et al. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S52–S60. doi: 10.1007/s00259-011-1989-4.
    1. Hubalewska-Dydejczyk A, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging. 2006;33(10):1123–1133. doi: 10.1007/s00259-006-0113-7.
    1. Sepulveda-Mendez J, et al. Specificity and sensitivity of 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun. 2012;33(1):69–79. doi: 10.1097/MNM.0b013e32834cecfe.
    1. Bombardieri E, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(7):1441–1448. doi: 10.1007/s00259-010-1473-6.
    1. Gabriel M, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–518. doi: 10.2967/jnumed.106.035667.
    1. Hofmann M, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–1757. doi: 10.1007/s002590100639.
    1. Rosch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011;40(23):6104–6111. doi: 10.1039/c0dt01504k.
    1. Valkema R, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–122. doi: 10.1053/snuc/2002.31025.
    1. Anthony LB, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32(2):123–132. doi: 10.1053/snuc.2002.31769.
    1. Waldherr C, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43(5):610–616.
    1. Bodei L, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30(2):207–216. doi: 10.1007/s00259-002-1023-y.
    1. Valkema R, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147–156. doi: 10.1053/j.semnuclmed.2006.01.001.
    1. Kwekkeboom DJ, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–2130. doi: 10.1200/JCO.2007.15.2553.
    1. Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012;2(5):481–501. doi: 10.7150/thno.4024.
    1. Teunissen JJ, et al. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relate Cancer. 2011;18(Suppl 1):S27–S51. doi: 10.1530/ERC-10-0282.
    1. Ginj M, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103(44):16436–16441. doi: 10.1073/pnas.0607761103.
    1. Cescato R, et al. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52(12):1886–1890. doi: 10.2967/jnumed.111.095778.
    1. Wild D, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52(9):1412–1417. doi: 10.2967/jnumed.111.088922.
    1. Putzer D, et al. Somatostatin receptor PET in neuroendocrine tumours: 68 Ga-DOTA0, Tyr3-octreotide versus 68 Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40(3):364–372. doi: 10.1007/s00259-012-2286-6.
    1. Virgolini I, et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001;12(Suppl 2):S41–S45. doi: 10.1093/annonc/12.suppl_2.S41.
    1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389–427. doi: 10.1210/er.2002-0007.
    1. Wang X, et al. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(12):1876–1885. doi: 10.1007/s00259-012-2231-8.
    1. Tulipano G, et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology. 2002;143(4):1218–1224. doi: 10.1210/endo.143.4.8716.
    1. Fani M, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52(7):1110–1118. doi: 10.2967/jnumed.111.087999.
    1. O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36(10):1902–1909.
    1. de Jong M, et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):13S–17S.
    1. Kunikowska J, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788–1797. doi: 10.1007/s00259-011-1833-x.
    1. Villard L, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30(10):1100–1106. doi: 10.1200/JCO.2011.37.2151.
    1. Savolainen S, et al. Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. Eur J Nucl Med Mol Imaging. 2012;39(3):548–549. doi: 10.1007/s00259-011-2036-1.
    1. Nayak TK, et al. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol. 2007;34(2):185–193. doi: 10.1016/j.nucmedbio.2006.11.006.
    1. Miederer M, et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14(11):3555–3561. doi: 10.1158/1078-0432.CCR-07-4647.
    1. Dodson H, Wheatley SP, Morrison CG. Involvement of centrosome amplification in radiation-induced mitotic catastrophe. Cell Cycle. 2007;6(3):364–370. doi: 10.4161/cc.6.3.3834.
    1. Giesel F, et al. Monitoring of perfusion changes after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy using contrast-enhanced ultrasound in liver metastatic neuroendocrine cancer. Eur J Nucl Med Mol Imaging. 2011;38(Suppl. 2):S117.
    1. Kulke MH, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338–345. doi: 10.1158/1078-0432.CCR-08-1476.
    1. Limouris GS, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35(10):1827–1837. doi: 10.1007/s00259-008-0779-0.
    1. Kratochwil C, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18(5):595–602. doi: 10.1530/ERC-11-0144.
    1. Pool SE, Kam B, Breeman WAP. Increasing intrahepatic tumour uptake of 111In-DTPA-octreotide by loco regional administration. Eur J Nucl Med Mol Imaging. 2009;36:S427.
    1. Kratochwil C, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16(10):2899–2905. doi: 10.1158/1078-0432.CCR-10-0004.
    1. Imhof A et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 29(17):2416–2423
    1. Sabet A, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-Octreotate. J Nucl Med. 2013;54:1857–1861. doi: 10.2967/jnumed.112.119347.
    1. Rolleman EJ, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9–15. doi: 10.1007/s00259-002-0982-3.
    1. Barone R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(Suppl 1):99S–106S.
    1. Wessels BW, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response–implications for radionuclide therapy. J Nucl Med. 2008;49(11):1884–1899. doi: 10.2967/jnumed.108.053173.
    1. Valkema R, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):83S–91S.
    1. Bodei L, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847–1856. doi: 10.1007/s00259-008-0778-1.
    1. Guerriero F, et al. Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int. 2013;2013:935351. doi: 10.1155/2013/935351.
    1. Jamar F, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30(4):510–518. doi: 10.1007/s00259-003-1117-1.
    1. Garkavij M, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084–1092. doi: 10.1002/cncr.24796.
    1. Sandstrom M et al (2012) Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 54(1):33–41
    1. De Jong M, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med. 2004;45(7):1168–1171.
    1. Konijnenberg M, et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med. 2007;48(1):134–142.
    1. Baechler S, et al. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy. Med Phys. 2012;39(10):6118–6128. doi: 10.1118/1.4752213.
    1. Forrer F, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138–1146. doi: 10.1007/s00259-009-1072-6.
    1. Hindorf C et al (2010) EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 37(6):1238–1250
    1. Lassmann M, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405–1412. doi: 10.1007/s00259-008-0761-x.
    1. Walrand S et al (2011) Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 38(7):1270–1280
    1. Arvold ND et al (2012) Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 83(3):e337–e343
    1. Pauwels S, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):92S–98S.
    1. Ezziddin S, et al. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate. Nuklearmedizin. 2013;52(5):170–177. doi: 10.3413/Nukmed-0581-13-05.
    1. Otte A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–1447. doi: 10.1007/s002590050476.
    1. Beauregard JM. et al (2011) Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 11:56–66
    1. Sabet A, et al. Outcome and toxicity of salvage therapy with Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:205–210. doi: 10.1007/s00259-013-2547-z.
    1. van Essen M. et al (2010) Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 51(3): 383–390
    1. Breeman WA, et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0, Tyr3]octreotate in a rat liver micrometastases model. Int J Cancer. 2003;104(3):376–379. doi: 10.1002/ijc.10952.
    1. Kaemmerer D, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009;15(46):5867–5870. doi: 10.3748/wjg.15.5867.
    1. Stoeltzing O, et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg. 2010;395(2):185–192. doi: 10.1007/s00423-009-0520-x.
    1. Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27(9):561–569. doi: 10.1089/cbr.2012.1276.
    1. Barber TW, et al. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38(1):64–71. doi: 10.1016/j.ejso.2011.08.129.
    1. van Essen M, et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(4):743–748. doi: 10.1007/s00259-007-0688-7.
    1. Claringbold PG, et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38(2):302–311. doi: 10.1007/s00259-010-1631-x.
    1. Fueger BJ, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med. 2001;42(12):1856–1862.
    1. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205–2218. doi: 10.1200/JCO.2012.46.3653.
    1. Bison SM, Haeck JC, Koelewijn SJ, Groen HC, Berndsen S, Melis M, Bernsen MR, de Jong M (2013) Optimization of combination of peptide receptor radionuclide therapy (PRRT) and temozolomide therapy using SPECT/CT and MRI in mice. Eur J Nucl Med Mol Imaging 40(suppl 2):S290(abstract)
    1. Nayak TK, et al. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol. 2008;35(6):673–678. doi: 10.1016/j.nucmedbio.2008.05.003.
    1. Yao JC, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523. doi: 10.1056/NEJMoa1009290.
    1. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23(18):3151–3171. doi: 10.1038/sj.onc.1207542.
    1. Pool SE, et al. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreaticneuroendocrine cancer. Cancer Res. 2013;73:12–18. doi: 10.1158/0008-5472.CAN-11-2089.
    1. Hubble D, et al. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging. 2010;37(10):1869–1875. doi: 10.1007/s00259-010-1483-4.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel